Physician profile
Frank J Hackl
NPI 1912030404
$1,633.26
in general payments reported to CMS, 2019-2025
36 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $230 · 2021: $554 · 2022: $218 · 2023: $149 · 2024: $57.32 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $222.26 | 2020-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $120.74 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $116.72 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.57 | 2020-2025 | Relistor |
| Assertio Therapeutics, INC. | $92.39 | 2019 | |
| Medtronic, INC. | $86.09 | 2021-2023 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $70.51 | 2021 | |
| Biodelivery Sciences International, INC. | $67.27 | 2020-2021 | |
| Pfizer INC. | $65.05 | 2019 | |
| Abbott Laboratories | $50.11 | 2021 | |
| Grt US Holding, INC. | $46.62 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $44.66 | 2020-2021 | |
| Nevro Corp. | $43.65 | 2021 | |
| Abbvie INC. | $40.33 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $36.18 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $35.62 | 2019 | |
| Saluda Medical Americas, INC. | $32.68 | 2025 | Evoke |
| Amgen INC. | $29.71 | 2020-2021 | |
| Eisai INC. | $25.56 | 2021 | |
| Si-Bone, INC. | $24.87 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $24.59 | 2019-2020 | |
| Ucb, INC. | $23.45 | 2025 | Bimzelx |
| Bioventus LLC | $19.97 | 2021 | |
| Indivior INC. | $19.07 | 2020 | |
| Boston Scientific Corporation | $18.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.33 | 2022 | |
| Medtronic USA, INC. | $17.06 | 2019 | |
| Daiichi Sankyo INC. | $15.79 | 2019 | |
| Sentynl Therapeutics, INC. | $15.33 | 2019 | |
| Valinor Pharma, LLC | $15.05 | 2025 | Movantik |
| Orexo US, INC. | $15.01 | 2023 | Zubsolv |
| Azurity Pharmaceuticals, INC. | $14.30 | 2025 | Horizant |
| Lilly USA, LLC | $13.73 | 2021 | |
| Ibsa Pharma INC. | $13.53 | 2021 | |
| Baudax Bio INC. | $12.63 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Hackl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.